Skip to content

Study · Animal study (in vivo) · rat · 1994

11 results

Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats.

Gardiner SM, Rakhit T, Kemp PA, March JE, Bennett T

British journal of pharmacology1 Feb 1994Cited by 25 (Europe PMC)

PMID7911721 (opens in a new tab)PMCIDPMC1909954 (opens in a new tab)DOI10.1111/j.1476-5381.1994.tb14778.x (opens in a new tab)PepBankPUB-07911721
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, VIP infusion caused dose-dependent depressor effects, a fall in blood pressure.

    In plain wordsIn rats, VIP infusion lowered blood pressure in a dose-dependent way.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseDepressor (blood pressure lowering) response
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.5-15 nmol/kg/h · 20 minAs given in this study (rat).

    Source sentences

    Summary
    VIP caused dose-dependent depressor and tachycardic effects that were not significantly different from those caused by equimolar doses of PACAP27.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, VIP infusion caused dose-dependent tachycardic effects, a rise in heart rate.

    In plain wordsIn rats, VIP infusion raised heart rate in a dose-dependent way.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseTachycardic (heart rate) response
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.5-15 nmol/kg/h · 20 minAs given in this study (rat).

    Source sentences

    Summary
    VIP caused dose-dependent depressor and tachycardic effects that were not significantly different from those caused by equimolar doses of PACAP27.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, the depressor and tachycardic effects of VIP were not significantly different from those of equimolar PACAP27.

    In plain wordsIn rats, VIP and PACAP27 had similar effects on blood pressure and heart rate at equal doses.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeDepressor and tachycardic effects versus PACAP27
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    PACAP27 at equimolar doses
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.5-15 nmol/kg/h · 20 minAs given in this study (rat).

    Source sentences

    Summary
    VIP caused dose-dependent depressor and tachycardic effects that were not significantly different from those caused by equimolar doses of PACAP27.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, the hindquarters vasodilator effects of VIP were greater than those of PACAP27 at the same doses.

    In plain wordsIn rats, VIP widened the blood vessels of the hindquarters more than PACAP27 at the same doses.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseHindquarters vasodilator effect versus PACAP27
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    PACAP27 at the same doses
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    7.5 and 15 nmol/kg/h · 20 minAs given in this study (rat).

    Source sentences

    Summary
    However, the hindquarters vasodilator effects of VIP (at 7.5 and 15 nmol kg-1 h-1) were greater than those of PACAP27 (at the same doses), and accompanied by reductions in renal and mesenteric flows and conductances.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, VIP at 7.5 and 15 nmol/kg/h was accompanied by reductions in renal and mesenteric flows and conductances.

    In plain wordsIn rats, VIP reduced blood flow to the kidneys and gut at the higher doses.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseRenal and mesenteric flows and conductances
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    7.5 and 15 nmol/kg/h · 20 minAs given in this study (rat).

    Source sentences

    Summary
    However, the hindquarters vasodilator effects of VIP (at 7.5 and 15 nmol kg-1 h-1) were greater than those of PACAP27 (at the same doses), and accompanied by reductions in renal and mesenteric flows and conductances.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

Studies that did not test the peptide alone6

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 06AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In conscious rats, the nitric oxide synthase inhibitor L-NAME significantly inhibited the hindquarters vasodilator effects of VIP and PACAP27.

    In plain wordsIn rats, blocking nitric oxide production with L-NAME reduced the widening of hindquarters blood vessels caused by VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEffect of L-NAME on hindquarters vasodilatation
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    No L-NAME
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    In the presence of the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; 11 mumol kg-1 h-1), there was significant inhibition of the hindquarters vasodilator effects of PACAP27 and VIP (at 7.5 and 15 nmol kg-1 h-1).
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 07AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In conscious rats given L-NAME, the renal and mesenteric vasoconstrictor effects of VIP were abolished.

    In plain wordsIn rats, blocking nitric oxide production with L-NAME removed the narrowing of kidney and gut blood vessels caused by VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEffect of L-NAME on renal and mesenteric vasoconstriction
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    No L-NAME
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    Under these circumstances the renal and mesenteric vasoconstrictor effects of VIP were abolished.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 08AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In conscious rats, the beta 2-adrenoceptor antagonist ICI 118551 reduced the hindquarters vasodilator responses to VIP and PACAP27.

    In plain wordsIn rats, a beta 2 receptor blocker reduced the widening of hindquarters blood vessels caused by VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEffect of ICI 118551 on hindquarters vasodilatation
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    No ICI 118551
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    The beta 2-adrenoceptor antagonist, ICI 118551 (670 nmol kg-1 bolus, 335 nmol kg-1 h-1 infusion), reduced the matched hindquarters vasodilator responses to PACAP27 (15 nmol kg-1 h-1) and VIP (7.5 nmol kg-1 h-1), and also abolished the renal vasoconstrictor effects of VIP.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 09AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In conscious rats, the beta 2-adrenoceptor antagonist ICI 118551 abolished the renal vasoconstrictor effects of VIP.

    In plain wordsIn rats, a beta 2 receptor blocker removed the narrowing of kidney blood vessels caused by VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEffect of ICI 118551 on renal vasoconstriction
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    No ICI 118551
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    The beta 2-adrenoceptor antagonist, ICI 118551 (670 nmol kg-1 bolus, 335 nmol kg-1 h-1 infusion), reduced the matched hindquarters vasodilator responses to PACAP27 (15 nmol kg-1 h-1) and VIP (7.5 nmol kg-1 h-1), and also abolished the renal vasoconstrictor effects of VIP.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 10AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In conscious rats, the AT1-receptor antagonist losartan augmented the hypotensive action of VIP.

    In plain wordsIn rats, the blood pressure drop caused by VIP was larger when losartan was also given.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseEffect of losartan on the hypotensive action of VIP
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    No losartan
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    The AT1-receptor antagonist, losartan potassium (20 mumol kg-1), had no significant effect on the haemodynamic response to PACAP27 (15 nmol kg-1 h-1), but augmented the hypotensive action of VIP (7.5 nmol kg-1 h-1).
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  6. 11AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In conscious rats given losartan, the renal and mesenteric vasoconstrictor effect of VIP converted to vasodilatation.

    In plain wordsIn rats, with losartan the narrowing of kidney and gut blood vessels caused by VIP turned into widening.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedEffect of losartan on renal and mesenteric responses to VIP
    Study

    ratn: not reported in source

    conscious, chronically instrumented Long Evans rats
    Comparator
    No losartan
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    This influence of losartan was associated with conversion of the renal and mesenteric vasoconstrictor effect of VIP to vasodilatation.
    1 context sentence
    Summary · context
    Regional haemodynamic responses to the homologous peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1.5-15 nmol kg-1 h-1) in conscious, chronically-instrumented, Long Evans rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.